Botnaru Victor, Munteanu Oxana, Rusu Doina
Pneumologia. 2015 Jan-Mar;64(1):46-50.
Pulmonary toxicity is a rare side effect of interferon treatment with a wide spectrum of lung tissue conditions, including interstitial pneumonitis, pulmonary sarcoidosis, bronchiolitis obliterans organizing pneumonia, pleural effusion, exacerbation of bronchial asthma, reversible pulmonary hypertension and acute respiratory distress syndrome. We report a case of interstitial pneumonitis in a patient treated with pegylated interferon α2-a and ribavirin for chronic hepatitis C virus infection, genotype 1. The case was marked by progression of the respiratory symptoms even after the withdrawn of the pegylated interferon. One-year treatment with systemic corticosteroid ensured a considerable resorption of CT lesions but only a moderate improvement of symptoms and diffusion capacity without a complete recovery.
肺毒性是干扰素治疗罕见的副作用,可导致多种肺组织病变,包括间质性肺炎、肺结节病、闭塞性细支气管炎伴机化性肺炎、胸腔积液、支气管哮喘加重、可逆性肺动脉高压和急性呼吸窘迫综合征。我们报告1例因慢性丙型肝炎病毒1型感染接受聚乙二醇化干扰素α2-a和利巴韦林治疗的患者发生间质性肺炎。该病例的特点是即使停用聚乙二醇化干扰素后呼吸道症状仍有进展。全身使用糖皮质激素治疗1年,CT病变有明显吸收,但症状和弥散功能仅中度改善,未完全恢复。